 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
12 News |  |
- || capromab pendetide (CYT 500) / Jazz
Clinical, Journal, Real-world evidence: Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer. (Pubmed Central) - Dec 2, 2021
Our findings suggest that Lu-PSMA radioligand therapy provides a significant response rate with a low toxicity profile. The evidence promotes greater efficacy of radioligand therapy in predominantly lymph node metastatic castration-resistant prostate cancer, and in individuals with chemotherapy-naïve status and lower levels of baseline PSA.
- || capromab pendetide (CYT 500) / Jazz
Clinical, Review, Journal: Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends. (Pubmed Central) - Nov 17, 2021
Here, we recapitulate the role of targeted functional imaging. We briefly mention the most popular radiotracers, their diagnostic accuracy in the primary staging of PCa, and impact on patient management.
- || capromab pendetide (CYT 500) / Jazz
Clinical, Review, Journal: Comparison of prostate-specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer. (Pubmed Central) - Oct 6, 2021
The merits and demerits of monoclonal antibodies, small molecule ligands, peptides, and aptamers for imaging of PCa and intraoperative guided surgery are extensively analyzed. Among all, urea-based ligands were found to be most successful in preclinical and clinical trials and show a major promise for future commercialization.
- || capromab pendetide (CYT 500) / Jazz
Review, Journal: Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives. (Pubmed Central) - Aug 8, 2021
Recently, investigators started to focus on treating prostate cancer patients in earlier disease stages and in combination with other compounds. This review gives a brief overview of the current state and the future perspectives of Lu labelled PSMA radioligand therapy.
- | capromab pendetide (CYT 500) / Jazz
Biomarker, Journal: 68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy. (Pubmed Central) - Jul 21, 2021
For a more comprehensive assessment, consideration could be given to the use of both I-mIBG and Ga-DOTATATE imaging scans. Because of the heterogeneity of distribution of molecular targets revealed by these techniques, a combination of both I-mIBG and Lu-DOTATATE molecular radiotherapy may possibly be more effective than either alone.
- capromab pendetide (CYT 500) / Jazz
[VIRTUAL] Patient travel challenges in the rra of PPRT () - Mar 27, 2021 - Abstract #ENETS2021ENETS_290;
Traveling while undergoing PRRT should be discussed with the patient by the clinical care team and nuclear medicine/nuclear radiology team prior to treatment to avoid any unwanted surprises. Patients can arrange their schedules accordingly if they are well informed about this process ahead of time.
- | capromab pendetide (CYT 500) / Jazz
Journal: Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate Lu-NNV003. (Pubmed Central) - Oct 22, 2020
Lu-NNV003 had a significant anti-tumour effect and a favourable toxicity profile. These results warrant further clinical testing in patients with CD37-expressing B cell malignancies.
- | capromab pendetide (CYT 500) / Jazz
Journal: Prostate-specific membrane antigen theranostics: therapy with lutetium-177. (Pubmed Central) - Aug 11, 2019
Several studies suggest that radionuclide therapy with Lu-PSMA has high activity and is well tolerated. Crucial to establishing this treatment in routine clinical management will be the generation of high-level evidence from prospective trials that can confirm the encouraging patient outcomes reported to date.
- | ProstaScint (indium labeled capromab pendetide) / Jazz, capromab pendetide (CYT 500) / Jazz
Journal: A Prospective Trial of Intensity Modulated Radiation Therapy (IMRT) Incorporating a Simultaneous Integrated Boost for Prostate Cancer: Long-term Outcomes Compared With Standard Image Guided IMRT. (Pubmed Central) - Jul 15, 2017
The addition of the SIB was associated with greater biochemical control but not toxicity. Modern imaging technology can be used to locally intensify the dose to tumors and spare normal tissues, producing very favorable long-term biochemical disease control.